All In Biotech

Drug Trial Radar · NCT05762276

A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants

A Phase 1, First-in-Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Mar 7, 2023

Primary completion

Jul 25, 2024

Study completion Jul 25, 2024

Sponsor

Lead sponsor
Axxium Life, Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.

Conditions

  • Hypercholesterolemia

Interventions

  • VXX-401Drug

    A synthetic PCSK9 peptide-based immunotherapy

  • PlaceboBiological

    Normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse eventsTime frame: 30 weeks
  2. ImmunogenicityTime frame: Baseline to Week 16, 20, 24, and 30
  3. ImmunogenicityTime frame: Baseline to Week 16, 20, 24, and 30
  4. Determine optimal VXX-401 dose regimenTime frame: Baseline to Week 16, 20, 24, and 30

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Northern Beaches Clinical Research

    Brookvale, New South Wales, Australia

  • Sutherland Shire Clinical Research

    Miranda, New South Wales, Australia

  • Emeritus Research

    Sydney, New South Wales, Australia

  • University of the Sunshine Coast (USC)

    Morayfield, Queensland, Australia

  • Emeritus Research

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.